TORONTO, June 18, 2021 /CNW/ - HLS Therapeutics Inc.
("HLS" or the "Company") (TSX: HLS), a pharmaceutical company
focused on central nervous system and cardiovascular markets,
announces voting results from its Annual Meeting of Shareholders
held in a virtual format on June 18,
2021.
A total of 28,701,084 Common Shares, or 89.70% of the total
Common Shares issued and outstanding, were voted by proxy at the
meeting. Details of the voting by individual director were as
follows:
|
Name of
Nominee
|
Votes
Cast
FOR
|
% of Vote Cast
FOR
|
Votes
WITHHELD
|
% of Votes
WITHHELD
|
|
William
Wells
|
26,239,157
|
98.42%
|
421,208
|
1.58%
|
|
Gilbert
Godin
|
26,658,368
|
99.99%
|
1,997
|
0.01%
|
|
Greg
Gubitz
|
26,657,885
|
99.99%
|
2,480
|
0.01%
|
|
J. Spencer
Lanthier
|
24,305,484
|
91.17%
|
2,354,881
|
8.83%
|
|
Yvon
Bastien
|
25,238,694
|
94.67%
|
1,421,671
|
5.33%
|
|
Rodney
Hill
|
22,879,834
|
85.82%
|
3,780,531
|
14.18%
|
|
Don
DeGolyer
|
25,241,351
|
94.68%
|
1,419,014
|
5.32%
|
|
Laura
Brege
|
22,873,887
|
85.80%
|
3,786,478
|
14.20%
|
|
John
Welborn
|
26,630,363
|
99.89%
|
30,002
|
0.11%
|
|
Norma
Beauchamp
|
26,623,535
|
99.86%
|
36,830
|
0.14%
|
HLS also confirms that shareholders approved the appointment of
Ernst & Young LLP as the Company's auditors as well as an
ordinary resolution approving certain proposed amendments to the
Company's Stock Option Plan and approving the unallocated options
thereunder.
ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a
pharmaceutical company focused on the acquisition and
commercialization of late-stage development, commercial stage
promoted and established branded pharmaceutical products in the
North American markets. HLS's focus is on products targeting the
central nervous system and cardiovascular therapeutic areas. HLS's
management team is composed of seasoned pharmaceutical executives
with a strong track record of success in these therapeutic areas
and at managing products in each of these lifecycle stages. For
more information, please visit: www.hlstherapeutics.com
SOURCE HLS Therapeutics Inc.